At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer.
The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells
11th December 2015
Oncology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given